About: KD-414

An Entity of Type: vaccine, from Named Graph: http://dbpedia.org, within Data Space: dbpedia.org

KD-414 is a COVID-19 vaccine candidate developed by Japanese biotechnology company KM Biologics Co. Results of a phase 1/2 clinical trial for this vaccine were released as a preprint in June 2022.

Property	Value
dbo:abstract	KD-414 is a COVID-19 vaccine candidate developed by Japanese biotechnology company KM Biologics Co. Results of a phase 1/2 clinical trial for this vaccine were released as a preprint in June 2022. (en)
dbo:wikiPageID	69577119 (xsd:integer)
dbo:wikiPageLength	3433 (xsd:nonNegativeInteger)
dbo:wikiPageRevisionID	1119594506 (xsd:integer)
dbo:wikiPageWikiLink	dbc:Inactivated_vaccines dbr:Intramuscular_injection dbr:COVID-19_vaccine dbr:Severe_acute_respiratory_syndrome_coronavirus_2 dbr:Japan dbc:Clinical_trials dbc:Japanese_COVID-19_vaccines dbr:Biotechnology
dbp:routesOfAdministration	dbr:Intramuscular_injection
dbp:target	dbr:Severe_acute_respiratory_syndrome_coronavirus_2
dbp:type	vaccine (en)
dbp:vaccineType	inactivated (en)
dbp:wikiPageUsesTemplate	dbt:Infobox_drug dbt:Portal_bar dbt:Reflist dbt:Short_description dbt:Use_dmy_dates dbt:Scholia dbt:COVID-19_pandemic dbt:COVID-19_pandemic_sidebar dbt:Vaccines dbt:COVID19-vaccine-stub dbt:Vaccine-stub
dcterms:subject	dbc:Inactivated_vaccines dbc:Clinical_trials dbc:Japanese_COVID-19_vaccines
rdf:type	owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:Vaccine dbo:Drug
rdfs:comment	KD-414 is a COVID-19 vaccine candidate developed by Japanese biotechnology company KM Biologics Co. Results of a phase 1/2 clinical trial for this vaccine were released as a preprint in June 2022. (en)
rdfs:label	KD-414 (en)
owl:sameAs	wikidata:KD-414 https://global.dbpedia.org/id/GChhZ
prov:wasDerivedFrom	wikipedia-en:KD-414?oldid=1119594506&ns=0
foaf:isPrimaryTopicOf	wikipedia-en:KD-414
is dbo:wikiPageWikiLink of	dbr:COVID-19_vaccination_in_Japan
is foaf:primaryTopic of	wikipedia-en:KD-414